市场调查报告书
商品编码
1439310
週边插入中心静脉导管 (PICC) 装置 - 全球市场回顾、竞争格局、市场预测 (2030)Peripherally Inserted Central Catheter (PICC) Devices - Market Insights, Competitive Landscape, and Market Forecast - 2030 |
2023年全球週边插入中心静脉导管(PICC)器械市场规模预计为9.7613亿美元,到2030年将达到13.2659亿美元,2024-2030年预测期间复合年增长率为5.29%。週边静脉置入中心静脉导管(PICC)设备的需求主要由产品组合的技术进步、产品上市增加和充足的报销等因素驱动,此外还有癌症和传染病等发病率的增加。预测期为 2024 年-2030年,预测期为2024-2030年。
週边静脉置入中心静脉导管(PICC)市场动态
癌症、传染病等疾病的持续上升正在推动週边插入中心静脉导管(PICC)市场的成长。例如,国际癌症研究机构International Agency for Research on Cancer进行的一项研究估计,2020 年全球报告了 1,930 万新癌症病例。
根据世界卫生组织(WHO)(2022)的数据,2020年,乳癌226万例,肺癌221万例,大肠直肠癌193万例,摄护腺癌141万例,摄护腺癌109万例。胃癌的通报。
此外,根据全球癌症观察站Global Cancer Observatory(2021)的数据,2020年全球报告了约544,352例非何杰金氏淋巴瘤病例和83,087例霍奇金淋巴瘤病例。根据同一数据,2020年全球报告了约474,519例白血病病例和176,404例多发性骨髓瘤病例。
根据全球癌症观察站Global Cancer Observatory(2023)公布的数据,2020年全球报告前列腺癌新发病例约141万例,预计到2040年这一数字将达到224万例。
根据世界卫生组织 (WHO) (2022) 的数据,2020 年全球约有 3,770 万人感染人类免疫缺乏病毒 (HIV)。此外,根据欧洲疾病预防和控制中心 (ECDC) (2021) 的数据,过去 30 年来,世卫组织欧洲区域WHO European Region有超过 220 万人被诊断和报告感染爱滋病毒。2020年,欧洲约有104,765人新诊断出爱滋病毒感染者。
PICC 装置用于为感染患者施用抗生素和抗真菌药物。根据美国疾病管制与预防中心发布的2021年数据,2020-2021年间,47.8%的18岁及以上美国成年人接种了流感疫苗。
然而,与使用 PICC 装置相关的併发症和产品召回的增加可能会限制週边插入中心静脉导管 (PICC) 装置市场的成长。
週边置入中心静脉导管(PICC)器械市场细分分析
在周边插入中心静脉导管(PICC)器械市场的设计领域,三腔室类别在2023年占52.26%的收入份额。这可能是由于三腔外周插入中心静脉导管 (PICC) 装置具有多种优点。
当需要多次输注时,三腔 PICC 是适当的。可以在一个进入部位进行多种不同的输注。每个通道可以单独输注。插管远端不同位置的三个通道和管腔可同时进行药物输注、血液采样和中心静脉压 (CVP) 监测。
此外,三腔导管具有三个输液通道,可同时施用多种治疗药物,使其成为 ICU 的首选。三腔导管通常用于给予食道癌患者药物和必要的静脉输液。
本报告提供了全球週边插入中心静脉导管(PICC)设备市场的研究和分析,包括市场规模和预测、驱动因素和挑战以及公司和产品概况。
Peripherally Inserted Central Catheter (PICC) Devices Market By Product Type (Power Injected Peripherally Inserted Catheters, Non-Power Injected/ Conventional Peripherally Inserted Central Catheters), Design (Single Lumen, Double Lumen, Triple Lumen), End-User (Hospitals, Ambulatory Surgical Centers, And Others) and geography is expected to grow at a steady CAGR forecast till 2030 owing to the increasing incidence of cancers and infectious diseases and the various technological advancements in product portfolio
The global Peripherally Inserted Central Catheter (PICC) Devices market was valued at USD 976.13 million in 2023, growing at a CAGR of 5.29% during the forecast period from 2024 to 2030 to reach USD 1,326.59 million by 2030. The demand for peripherally inserted central catheter devices is primarily being boosted owing to the key factors such as the increasing incidence of cancers, and infectious diseases, among others, technological advancements in product portfolio, and proper reimbursement coupled with increasing product launches, thus creating a positive market growth for the Peripherally Inserted Central Catheter (PICC) Devices market during the forecast period from 2024-2030.
Peripherally Inserted Central Catheter (PICC) Devices Market Dynamics:
The continuous rise in the cases of cancer, infectious, and other diseases is driving the growth of the peripherally inserted central catheter devices market. For instance, the study conducted by the International Agency for Research on Cancer mentioned that worldwide, an estimated number of 19.3 million new cancer cases were reported in 2020.
According to data cited by the World Health Organization 2022, worldwide around 2.26 million cases of breast, 2.21 million cases of lung, 1.93 million cases of colon and rectum, 1.41 million cases of prostate, and 1.09 million cases of stomach cancer were reported in 2020.
Also, as per the Global Cancer Observatory 2021 data, globally around 544,352 cases of Non-Hodgkin lymphoma and 83,087 cases of Hodgkin lymphoma were reported in 2020. As per the same source globally around 474,519 leukemia cases and nearly 176,404 cases of multiple myeloma were reported in 2020.
The data published by Global Cancer Observatory (2023) says that globally around 1.41 million new cases of prostate cancer were reported in 2020 and by 2040 this number is expected to reach 2.24 million.
According to World Health Organization (WHO) 2022, globally there were around 37.7 million people suffering from human immunodeficiency virus (HIV) in year 2020. Also, as per the European Centre for Disease Prevention and Control (ECDC) 2021, over the course of the last three decades, over 2.2 million people have been diagnosed and reported with HIV in the WHO European Region. In 2020, nearly 104,765 people were newly diagnosed with HIV in the European region.
PICC devices are employed in delivery of antibiotics and antifungal medicines in patients suffering from infectious diseases. According to the data cited in 2021 by Centers for Disease Control and Prevention, 47.8% percent of US adults aged 18 and over received an influenza vaccination in the 2020-2021 duration.
However, complications associated with the use of PICC devices and the increasing number of product recalls may restrict the growth of the peripherally inserted central catheter devices market.
Peripherally Inserted Central Catheter (PICC) Devices Market Segment Analysis:
Peripherally Inserted Central Catheter (PICC) Devices market By Product type (Power Injected Peripherally Inserted Catheters, Non-Power Injected/ Conventional Peripherally Inserted Central Catheters), Design (Single Lumen, Double Lumen, Triple Lumen), End-User (Hospitals, Ambulatory Surgical Centers, And Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)
In the design segment of the peripherally inserted central catheter devices market, the triple lumen category held a revenue share of 52.26% in the year 2023. This can be ascribed to the various advantages associated with triple lumen peripherally inserted central catheter (PICC) devices.
Triple lumen PICC are suitable for use when multiple infusions are required to be performed. It allows to run several different infusion with only one access site. It offers separate infusion for each channel. It has three channels and lumens present at different positions on the distal cannula which provide ports for simultaneous drug infusion, blood drawing, and central venous pressure (CVP) monitoring.
Moreover, triple lumen catheters are most preferred ICU settings for their three infusion channels that allows for simultaneous administration of multiple therapies. Triple lumen catheters are routinely employed for the delivery of medications and other necessary fluids to patients with esophageal cancer.
In patients under intensive care and patients undergoing bone marrow transplants (BMT), triple lumen catheters are mostly preferred over other types. For example, Poly Per-Q-Cath3 by BD is an example of triple lumen catheter indicated for short or long term peripheral access to the central venous system for intravenous therapy and blood sampling.
Therefore, owing to the above-mentioned factors, the triple lumen category is expected to hold a respectable revenue share in the peripherally inserted central catheter (PICC) devices market during the forecast period.
North America is expected to dominate the overall Peripherally Inserted Central Catheter (PICC) Devices Market:
In the PICC devices global market, North America is expected to hold the largest share of 46.65% in the year 2023. Owing to the significance of key growth factors such as the increasing incidence of cancer, infectious, and other diseases, along with their risk factors, increasing healthcare expenditure, favorable reimbursement policies, rising research and development activities in the region including launches and approvals, among others, the market for peripherally inserted central catheter devices is expected to witness prosperity in the region during the forecast period from 2024-2030.
In the United States, the rising cases of chronic disorders such as cancers, respiratory disorders, gastrointestinal disorders in the region is likely to increase the demand for PICC.
For instance, according to the Centre for Disease Control and Prevention (CDC) 2020, Cystic fibrosis (CF), a genetic disorder that causes problems with breathing and digestion affects about 35,000 people in the United States, every year on an average.
In addition, people suffering from cystic fibrosis who need intravenous (IV) antibiotic treatments is for more than just a few days, such as during an exacerbation, which could potentially raise the demand for PICC catheters.
The Public Health Agency of Canada (2023) report stated that in 2020, the rate of active tuberculosis in Canada was 4.7 per 100,000 population. The peripherally inserted central catheters (PICCs) are frequently used to deliver intravenous antimicrobial therapy. Thus, the increasing prevalence of such infections in the country will propel the demand for PICC devices. Canada Institute for Health Information (CIHI) 2023, in 2021-2022, there were almost 2.9 million acute inpatient hospitalizations in Canada, up from 2.7 million visits in 2020-2021. The rising figures of hospitalizations in the country will increase the demand for PICC devices as these devices will be used to administer medications, fluids, and blood products to the hospitalized patients.
Thus, the interplay of all the above-mentioned factors would potentially help in driving the North America Peripherally Inserted Central Catheter (PICC) Devices market forward during the forecast period.
Peripherally Inserted Central Catheter (PICC) Devices Market Key Players:
Some of the key market players operating in the Peripherally Inserted Central Catheter (PICC) Devices market include B. Braun Melsungen AG, AngioDynamics, Cardinal Health, BD, Teleflex Incorporated, Argon Medical, Cook Group, ICU Medical Inc., Medical Components Inc., Access Vascular, Vygon, Meditech Devices, Biowy Corporation, Polymedicure, Footprint Medical Inc., SILMAG GROUP, pfm medical ag, Healthline Medical Products, INSUNG MEDICAL Co., Ltd., Equipos de Biomedicina de Mexico, S.A. de C.V, and others.
Recent Developmental Activities in the Peripherally Inserted Central Catheter (PICC) Devices Market:
In May 2022, Access Vascular, Inc., received the US FDA 510(k) clearance for its HydroPICC® Dual-Lumen catheter which has been designed and constructed using the same proprietary hydrophilic biomaterial as AVI's single-lumen HydroPICC® and HydroMID® catheters, with the aim to reduce complications such as occlusions, replacements, Deep Vein Thrombosis and phlebitis associated with use of multiple lumen catheters.
In March 2020, Biowy PICC-S kit received 510(k) clearance from the US FDA.
In March 2020, Access Vascular, Inc. received FDA clearance for the second generation of its HydroPICC, which demonstrated an average of 97% less thrombus accumulation on its surface compared to a standard polyurethane catheter.
Key Takeaways from the Peripherally Inserted Central Catheter (PICC) Devices Market Report Study
Market size analysis for current Peripherally Inserted Central Catheter (PICC) Devices market size (2023), and market forecast for 5 years (2024-2030)
The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the Peripherally Inserted Central Catheter (PICC) Devices market.
Top key product/services/technology developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years
Key companies dominating the global Peripherally Inserted Central Catheter (PICC) Devices market.
Various opportunities available for the other competitor in the Peripherally Inserted Central Catheter (PICC) Devices market space.
What are the top-performing segments in 2023? How these segments will perform in 2030?
Which are the top-performing regions and countries in the current Peripherally Inserted Central Catheter (PICC) Devices market scenario?
Which are the regions and countries where companies should have concentrated on opportunities for Peripherally Inserted Central Catheter (PICC) Devices market growth in the coming future?
Target Audience who can be benefited from this Peripherally Inserted Central Catheter (PICC) Devices Market Report Study
Peripherally Inserted Central Catheter (PICC) Devices products providers
Research organizations and consulting companies
Peripherally Inserted Central Catheter (PICC) Devices -related organizations, associations, forums, and other alliances
Government and corporate offices
Start-up companies, venture capitalists, and private equity firms
Distributors and Traders dealing in Peripherally Inserted Central Catheter (PICC) Devices
Various End-users who want to know more about the Peripherally Inserted Central Catheter (PICC) Devices market and the latest technological developments in the Peripherally Inserted Central Catheter (PICC) Devices market.
Frequently Asked Questions for the Peripherally Inserted Central Catheter (PICC) Devices Market:
Peripherally Inserted Central Catheter (PICC) device is a thin and flexible tube which is inserted into a vein to give intravenous fluids, blood transfusions, chemotherapy, and other drugs.
The global Peripherally Inserted Central Catheter (PICC) devices market was valued at USD 976.13 million in 2023, growing at a CAGR of 5.29% during the forecast period from 2024 to 2030 to reach USD 1,326.59 million by 2030.
The demand for Peripherally Inserted Central Catheter (PICC) devices is primarily being boosted owing to the key factors such as the increasing incidence of cancer, and infectious diseases, among other, technological advancement in the product portfolio, and proper reimbursement coupled with increasing product launches, thus creating a positive market growth of the Peripherally Inserted Central Catheter (PICC) Devices market during the forecast period from 2024-2030.
Some of the key market players operating in the Peripherally Inserted Central Catheter (PICC) devices include B. Braun Melsungen AG, AngioDynamics, Cardinal Health, BD, Teleflex Incorporated, Argon Medical, Cook Group, ICU Medical Inc., Medical Components Inc., Access Vascular, Vygon, Meditech Devices, Biowy Corporation, Polymedicure, Footprint Medical Inc., SILMAG GROUP, pfm medical ag, Healthline Medical Products, INSUNG MEDICAL Co., Ltd., Equipos de Biomedicina de Mexico, S.A. de C.V, and others.
North America is expected to dominate the overall Peripherally Inserted Central Catheter (PICC) Devices market during the forecast period from 2024-2030. Owing to the significance of key growth factors such as the increasing incidence of cancer, infectious, and other diseases, along with their risk factors, increasing healthcare expenditure, favourable reimbursement policies, rising research and development activities in the region including launches and approvals, among others, the market for peripherally inserted central catheter devices is expected to witness prosperity in the region during the forecast period from 2024-2030.